Emanuele Ostuni
Head of Europe Cell and Gene Therapy, Novartis Oncology
Emanuele is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees the commercialization of this portfolio in Europe.
Emanuele has been with Novartis since 2012. He joined the Sandoz Division with the Global Strategy Team, where he managed the collaborations with Novartis Pharmaceuticals and Alcon. He then became Head of Specialty and Hospital Franchises, Central/Eastern Europe, where he developed a specialty expansion strategy. Emanuele later served as Business Unit Head, Rx in Romania. In this role he grew the team to drive the expansion into CNS, respiratory, and rheumatology franchises.
Prior to joining Novartis in Europe he was based in the USA where he was Vice President of Business Development at Nano Terra, Engagement Manager at McKinsey & Co and a Senior Research Investigator at Surface Logix, where he helped to establish the company’s drug discovery platform.
Emanuele holds a PhD in Physical Chemistry from Harvard University and BS and MS degrees in chemistry from Georgetown University.
Head of Europe Cell and Gene Therapy, Novartis Oncology
Emanuele is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees the commercialization of this portfolio in Europe.
Emanuele has been with Novartis since 2012. He joined the Sandoz Division with the Global Strategy Team, where he managed the collaborations with Novartis Pharmaceuticals and Alcon. He then became Head of Specialty and Hospital Franchises, Central/Eastern Europe, where he developed a specialty expansion strategy. Emanuele later served as Business Unit Head, Rx in Romania. In this role he grew the team to drive the expansion into CNS, respiratory, and rheumatology franchises.
Prior to joining Novartis in Europe he was based in the USA where he was Vice President of Business Development at Nano Terra, Engagement Manager at McKinsey & Co and a Senior Research Investigator at Surface Logix, where he helped to establish the company’s drug discovery platform.
Emanuele holds a PhD in Physical Chemistry from Harvard University and BS and MS degrees in chemistry from Georgetown University.
Articles: Emanuele Ostuni
Cell & Gene Therapy: Command? Consent? Collaborate!
Opinion / Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the myriad benefits of collaborative, as opposed to command, leadership, the impact of company and team culture on the innovation journey, and why we must not confuse collaboration with consensus. In a recent…
Cell & Gene Therapies: Transforming our Vision of Healthcare Systems
Opinion / Emanuele Ostuni, head of cell & gene therapy for Novartis Oncology in Europe, outlines how stakeholders across the biopharmaceutical value chain can surf the wave of innovation that breakthrough therapies such as CAR-T represent. Waves and Innovation CAR-T therapies are the frontrunners of a wave of amazing biomedical innovation Over the summer, I watched waves…
Latest Report
